Category: Epidarex Portfolio News
“TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis” published in American Journal of Respiratory and Critical Care Medicine Paper demonstrates first in class TMEM16A chloride channel potentiators, to accelerate mucociliary clearance Co-authored by researchers from University of Sussex, University of North…
Pegcetacoplan met the primary endpoint in the PEGASUS study, demonstrating superiority to eculizumab (p<0.0001) with an improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16 Safety profile of pegcetacoplan was comparable to eculizumab in this study Conference call scheduled today at 8:30…
First program from the Topas platform to enter clinical testing PM203 is one of several proprietary programs being developed by Topas Pemphigus vulgaris is an orphan indication that currently has no cure Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private platform company leveraging the natural…
To accelerate development of molecular targeted systemic radiotherapy (SR, PRRT) based on its clinical stage technology Edinburgh, United Kingdom – Edinburgh Molecular Imaging Ltd (EMI), a company developing theragnostic agents targeting cancer, today announces the closing of a £3.1 million financing, which will be used to advance…
Epidarex’s therapeutic discovery engine will identify innovative early stage assets, providing hands-on scientific support and funding to drive drug discovery projects Exeed will mould and de-risk opportunities, making them ready for company creation and Series A investment Co-founder Dr. Henning Steinhagen appointed as CEO …
18 month project in collaboration with University of Leeds and Medicines Discovery Catapult will deliver a new compound for treatment of thrombosis Currently available anticoagulants carry high risk of bleeding Leeds, UK, 02 December 2019: LUNAC Therapeutics (LUNAC), a UK based drug discovery company focused…
Novel anticoagulants to minimise bleeding risk by targeting activated Factor XII Builds on a decade of academic research into Factor XII Investment round led by Epidarex Capital and University of Leeds Leeds, UK, 14 November 2019: LUNAC Therapeutics (LUNAC), a UK based drug discovery…
Support for clinical development up to end of Phase 2 for ETD002, first-in-class TMEM16A potentiator for the treatment of all cystic fibrosis patients Milestone Funding through Cystic Fibrosis Foundation’s Therapeutics Development Award programme Brighton, UK, 15 October 2019: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company…